ABBV - AbbVie Inc.

NYSE - NYSE Delayed Price. Currency in USD
+2.13 (+3.31%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close 64.43
Open 65.04
Bid 66.44 x 1800
Ask 0.00 x 1400
Day's Range 64.97 - 66.88
52 Week Range 62.66 - 100.23
Volume 9,480,385
Avg. Volume 10,405,380
Market Cap 98.408B
Beta (3Y Monthly) 0.69
PE Ratio (TTM) 24.30
EPS (TTM) 2.74
Earnings Date Oct 31, 2019 - Nov 4, 2019
Forward Dividend & Yield 4.28 (6.64%)
Ex-Dividend Date 2019-07-12
1y Target Est 85.25
Trade prices are not sourced from all markets
  • Stocks To Buy: Is It Time To Buy Or Sell These Large-Cap Stocks?
    Investor's Business Daily

    Stocks To Buy: Is It Time To Buy Or Sell These Large-Cap Stocks?

    Looking for stocks to buy? Get analysis of large-cap stocks like Amazon, Alibaba and Dow Jones stocks GE and Microsoft to see if it's time to buy — or sell.

  • AbbVie Rises 3%

    AbbVie Rises 3% - AbbVie (NYSE:ABBV) rose by 3.05% to trade at $66.39 by 12:56 (16:56 GMT) on Monday on the NYSE exchange.

  • AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA

    AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA

    AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives FDA approval for treating rheumatoid arthritis under the trade name of Rinvoq. Shares up.

  • 5 Biggest New Drug Approvals Potentially on the Way in 2019
    Motley Fool

    5 Biggest New Drug Approvals Potentially on the Way in 2019

    FDA approvals for these drugs could translate to billions of dollars for a few companies.

  • How AbbVie Plans To Take On Pfizer, Lilly — And Kick Its Humira Habit
    Investor's Business Daily

    How AbbVie Plans To Take On Pfizer, Lilly — And Kick Its Humira Habit

    Shares of AbbVie leapt higher Friday after the Food and Drug Administration approved its new rheumatoid arthritis treatment — a potential rival to drugs from Eli Lilly and Pfizer.

  • How Merck Could Ride 'The Keytruda Wave' To Dominate These Rivals
    Investor's Business Daily

    How Merck Could Ride 'The Keytruda Wave' To Dominate These Rivals

    Merck stock jumped Friday after an analyst initiated coverage of the Dow Jones pharma giant with an outperform rating, citing "the Keytruda wave." Keytruda is a blockbuster cancer drug.

  • MarketWatch

    FDA approves AbbVie's Rinvoq to treat moderate-to-severe RA

    The U.S. Food and Drug Administration has approved AbbVie Inc's Rinvoq, a JAK kinase inhibitor, to treat moderate-to-severe rheumatoid arthritis in adults for whom methotrexate hasn't worked, AbbVie announced Friday. The pharmaceutical company said Rinvoq should be available in the U.S. later this month. "Despite the availability of multiple treatment options with varying mechanisms of action, many patients still do not achieve clinical remission or low disease activity - the primary treatment goals for rheumatoid arthritis," said Roy Fleischmann, a clinical professor at the University of Texas Southwestern Medical Center at Dallas who led one of AbbVie's clinical trials of Rinvoq. "With this FDA approval, Rinvoq has the potential to help additional people living with RA achieve remission who have not yet reached this goal." The European Medicines Agency and regulatory authorities in Canada and Japan are still reviewing the drug. Shares of AbbVie were up 2.2% Friday afternoon, though they've fallen 30% in the year to date amid investor worry over declining sales of the company's blockbuster drug Humira. The stock also took a hit in June when the AbbVie said it would be acquiring Botox-maker Allergan Plc in a deal worth around $63 billion. The S&P 500 has gained 15.2% so far this year.

  • AbbVie Stock Is Poised To Become A Top 5 Pharma — But Should You Buy It?
    Investor's Business Daily

    AbbVie Stock Is Poised To Become A Top 5 Pharma — But Should You Buy It?

    AbbVie stock fell on its $63 billion plan to acquire Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?

  • Reuters

    UPDATE 2-AbbVie prices new rheumatoid arthritis drug at $59,000/yr

    AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising competition for Humira, its blockbuster therapy for the same condition. A four-week supply of Humira, the world's best-selling medicine, has a list price of about $5,174, amounting to more than $60,000 for a year. Humira brought in global revenue of $4.87 billion in the second quarter, but sales have been hit by competition from cheaper rivals in Europe, and AbbVie in June announced a deal to buy Botox-maker Allergan Plc for $63 billion to reduce dependence on the drug.

  • PR Newswire

    AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis

    - RINVOQ (upadacitinib) met all primary and ranked secondary endpoints across a variety of patients with moderately to severely active rheumatoid arthritis - Durable remission rates with RINVOQ (as ...

  • Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe

    Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe

    The EMA accepts Gilead (GILD) and Galapagos' MAA for filgotinib as a treatment for rheumatoid arthritis.

  • The Top Pharma Stocks for 2019

    The Top Pharma Stocks for 2019

    Find out how the pharmaceutical industry is thriving, the new drugs that are coming to market, and the top pharmaceutical stocks for 2019.

  • 13 High-Yield Dividend Stocks to Watch

    13 High-Yield Dividend Stocks to Watch

    High-yield dividend stocks have gained even more allure lately in the face of shrinking bond yields. However, while a handful are ready buys right now, several more sport alluring yields - at least 5%, and up into the double digits - but need a little more time to simmer before it's time to dip in.Patience is a virtue in life. That's particularly true in the investing world. It's even true across investing disciplines. Sober value investors wait for their price before buying, but disciplined market technicians also know to wait for the proper setup before trading.Sometimes, you need to wait for a fundamental catalyst to make your trade worth making. Other times, it's simply a matter of waiting for the right price. But the key is having the self-control to wait for your moment. Lack of patience can be a portfolio killer."We tell our clients during the onboarding process that we won't be investing their entire portfolio on day one," explains Chase Robertson, Managing Partner of Houston-based RIA Robertson Wealth Management. "We tend to average into our portfolios over time as market conditions warrant, and we're not opposed to having large cash positions. Our clients thank us in the end."Today, we're going to look at 13 high-yield dividend stocks to keep on your watch list. All are stocks yielding over 5% that you probably could buy today, but all have their own unique quirks that might make it more prudent to watch them a little longer rather than jump in with both feet. SEE ALSO: 57 Dividend Stocks You Can Count On in 2019

  • 5 Top Cancer-Fighting Stocks to Buy Now
    Motley Fool

    5 Top Cancer-Fighting Stocks to Buy Now

    Each of these healthcare companies takes a different approach to fighting cancer, but all have what it takes to be long-term winners in your portfolio.

  • How Tesla has Become Most Profitable Short Bet at $2.75 Billion

    How Tesla has Become Most Profitable Short Bet at $2.75 Billion

    Tesla short sellers may reap even bigger profits if CEO Musk fails to revive the electric car company.

  • Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study

    Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study

    Lilly's (LLY) Taltz is an important revenue driver for Lilly. Top-line data from a study shows that Taltz helps more plaque psoriasis patients achieve 100% skin clearance compared to Tremfya.

  • Financial Times

    Correction: Allergan sale

    Allergan chief executive Brent Saunders disclosed the role of JPMorgan and Wachtell, Lipton, Rosen & Katz asadvisers to the company on its planned sale to AbbVie, not AbbVie chief executive Richard Gonzalez ...

  • Morningstar

    Defensive Stocks on Sale

    Recession worries have once again gripped the stock market. U.S. bond yields are falling, the yield curve is inverting, and pundits are prognosticating. Of course, Morningstar isn't in the business of predicting where the market is headed.

  • Financial Times

    Elliott bags Goldman’s Barg

    Top advisory shops, including the likes of Goldman Sachs and Morgan Stanley, have long shunned activists for fear of alienating their corporate clients. As a result, shareholder activism has become a lucrative business for banks hoping to cosy up to corporates in search of future business and hefty fees.

  • Should Value Investors Consider AbbVie (ABBV) Stock Now?

    Should Value Investors Consider AbbVie (ABBV) Stock Now?

    Let's see if AbbVie Inc. (ABBV) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

  • 5 Biggest New Drugs Approved in 2019 So Far
    Motley Fool

    5 Biggest New Drugs Approved in 2019 So Far

    And the one big pharma most likely to benefit the most.

  • Financial Times

    JPMorgan Chase set to scoop record fee for Allergan sale

    JPMorgan Chase is poised to collect the largest individual fee to a bank for selling a company, earning $123m for advising Botox-maker Allergan on a planned $63bn sale to US pharmaceutical group AbbVie. the $120m paid to Morgan Stanley for advising US agribusiness Monsanto on its $66bn sale to Germany’s Bayer in 2016, according to data from Dealogic. The details of the fee arrangement were disclosed by Allergan this week as it prepares for a shareholder vote on its sale to Chicago-based AbbVie.

  • InvestorPlace

    10 Medical Marijuana Stocks to Cure Your Portfolio

    Editor's note: This story was previously published in April 2019. It has since been updated and republished.Invariably, no other investment class generates as much interest and controversy as marijuana stocks. Within a generation, public sentiment toward legalization shifted dramatically from strongly opposed to mostly supportive. This is largely due to demographics, as the more progressive millennials replace older Americans in positions of influence.Additionally, marijuana stocks represent a viable economic channel that can help bridge the gap for many states' financial issues. For instance, green-friendly Colorado enjoys significant tax revenues from its botanical industry. I don't see this trend changing for the worse anytime soon, as awareness and popularity is only increasing.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Stocks Under $7 to Invest in Now Of course, cannabis isn't without its controversies. Primarily, the federal government classifies marijuana as a Schedule I drug, putting it on par with hardcore narcotics like cocaine. Thus, no matter how liberal some states become toward their agricultural ambitions, the specter of federal oversight and crackdowns keeps many entrepreneurs and businesses away. * 7 Biometric Stocks to Watch as AI Rises However, we have one critical exception to the rule: marijuana stocks that specialize in medicinal and therapeutic benefits. For one thing, medical cannabis mitigates the stereotypical image of potheads and general no-gooders. Plus, people experiment with pharmaceuticals all the time. Why not allow these same patients the choice for natural alternatives?More critically for marijuana stocks, the medicinal aspect offers the best chance for international acceptance. Currently, very few jurisdictions allow recreational weed. Given the abundance of traditional and conservative nations, a green world is unlikely. But as Thailand and South Korea demonstrated, medical cannabis is a much easier sell.As a result, you want exposure not just to marijuana stocks, but also to the therapeutic element. Here are 10 names to consider: AbbVie (ABBV)Whenever you have a discussion about cannabis stocks, chances are, AbbVie (NYSE:ABBV) isn't the first name you think about. One of the healthcare sector's blue chips, ABBV stock has soared on its vast therapeutic pipeline. We're talking mainstream solutions for common ailments and diseases like arthritis and plaque psoriasis.Source: Shutterstock Still, AbbVie maintains some botanical credibility with its Marinol therapy. A synthetic cannabis-based drug, Marinol addresses chemotherapy-related side effects, such as vomiting or nausea. In addition, it helps restore appetite among AIDS patients.Of course, you should note that Marinol isn't among AbbVie's top-selling products. Therefore, you're only getting limited exposure to cannabis with ABBV stock. But based on the extreme volatility of marijuana stocks, that isn't such a bad gig. Emerald Health Therapeutics (EMHTF)Not that I would know, but growing cannabis allegedly isn't rocket science. With the right conditions, the right equipment and a reasonable car, anyone can grow their stash. But cultivating the plant so that it addresses specific ailments and symptoms? That takes real effort, which is where Emerald Health Therapeutics (OTCMKTS:EMHTF) comes in.Source: Shutterstock Rather than just pumping out the green stuff, Emerald deliberately seeks out the strains most effective in addressing patients' needs. The company provides a wide selection of strains, which range in weight, tetrahydrocannabinol (THC) content, and cannabidiol (CBD) strength. Their impressive portfolio should lift EMHTF stock over the long run, as interest in CBD products accelerates. * 8 Dividend Aristocrat Stocks to Buy Now No Matter What It's important to be careful with pot stocks, though. On a year-to-date basis, EMHTF stock is down nearly 40%. While all cannabis stocks suffer volatility risk, Emerald's concentration on medicinal weed should help mitigate downside pressure. Aurora Cannabis (ACB)I've spent a lot of time discussing Aurora Cannabis (NYSE:ACB), and I don't mean to keep double-dipping into this company. Still, I keep going back for a reason: ACB stock is an excellent play within the medical-marijuana market.A key factor in my bullishness for Aurora is its management team. In my view, they're making smart decisions through their acquisitive strategy.Rather than merely focusing on outright capacity, they're looking out over the horizon. Aurora's buyout of Whistler Medical Marijuana gave the organization significant leverage in medical cannabis due to Whistler's extensive genetics bank.Furthermore, ACB stock is a strong performer. Since the January opener, shares have skyrocketed roughly 70% before plummeting but still has added 24% this year. The inevitable correction should be only temporary. Among marijuana stocks, Aurora is exceptionally well-positioned for sustainable growth. Cronos Group (CRON)One of the top names among major marijuana stocks, Cronos Group (NASDAQ:CRON) naturally attracts a lot of attention. This time, though, they're attracting the wrong kind.Source: Shutterstock Prior to its earnings report for the second quarter, I worried about the company's revenue target.Hit or exceed it, and management can stave off criticism, but speculators looking for a discounted price may want to put CRON stock back on their radar. Since the beginning of March, Cronos has shed more than 28%. However, the magnitude of volatility has declined noticeably in the past few days. * 5 Cheap Stocks to Buy Now That the Fed Cut Rates Plus, Cronos has international legitimacy among medicinally focused cannabis stocks. Featuring partnerships and joint ventures across five continents, the company is ahead of the game. CannTrust (CTST)In business, even the green kind, you can't get ahead of yourself. So while lucrative opportunities exist in the international sector, CannTrust (NYSE:CTST) remains firmly committed to winning its native Canadian market.At the same time, CannTrust can't afford to ignore the rest of the world. Although Canada becoming the first G7 nation to legalize recreational weed generated headlines, our northern neighbors alone can't support this burgeoning industry.Therefore, management has focused on the growth and capacity narrative to compete effectively at home and, later, abroad.To achieve the second leg of this journey, CannTrust teamed up with Denmark's Stenocare to distribute medical cannabis products in that country.It also inked a partnership with an Australian firm for similar distribution arrangements. While it's not the most common name among marijuana stocks, CTST stock provides a risky, but viable, opportunity. Innovative Industrial Properties (IIPR)Most marijuana stocks focus on the industry's front face; namely, production. As I mentioned earlier, marijuana isn't that difficult to grow. So long as you have the green light legally, the physical barrier to entry is relatively short.But the real challenge, though, is finding a consistent source of financing. This is where Innovative Industrial Properties (NYSE:IIPR) lends a helping hand.Despite momentum toward legalization, several financial institutions shy away from cannabis ventures.Innovative Industrial plugs the gap, offering critical capital through its leaseback business model. * 10 Stocks to Buy on the Trade War Dip Thanks to the company's tremendous utility, IIPR stock has lit up the markets. Shares are currently up 123% YTD. Technically, IIPR may have gotten a bit overheated. That said, I wouldn't get too greedy looking for the perfect entry point. Innovative Industrial levers a proven business model that is only increasing in relevancy. Terra Tech (TRTC)Everyone recognizes cannabis stocks for two things: their incredible potential and their equally incredible volatility. Unfortunately, stakeholders of medical-cannabis producer Terra Tech (OTCMKTS:TRTC) find themselves in the latter category.So far this year, TRTC stock is down around 35%.And the bad news doesn't end there. Unlike many other marijuana stocks, Terra Tech has had trouble generating top-line growth.In its most recent earnings report for the second quarter, 2019 the company reported $10.37 million in sales. After two consecutive down quarters, this could signal that TRTC is redeemable.So why take a bet on TRTC stock? First, its vertically integrated organization may facilitate significant efficiencies as political momentum increases. Second, I dig their leadership team. The head execs are experts in finance, which should prove beneficial in properly navigating TRTC across choppy waters. Charlotte's Web (CWBHF)When most people look at Charlotte's Web (OTCMKTS:CWBHF), they're thinking that they missed the boat. After all, CWBHF stock has jumped 78% since the beginning of this year.Source: Shutterstock From the opening price of April, Charlotte's Web shares gained a ridiculous 16%.As much as I love marijuana stocks, I'm fairly certain that this cannabis firm is due for a pullback. But once that occurs, I wouldn't waste too much time squabbling over the granularity.Instead, I'd consider what our own Matt McCall had to say. Thanks to the popularity of CBD, Charlotte's Web's CBD-based products could be distributed across mainstream retail channels. * 10 Cyclical Stocks to Buy (or Sell) Now Unquestionably, such an event would launch CWBHF stock into the stratosphere. Moreover, because most CBD products contain no trace of THC, they don't fall under severe federal guidelines. Therefore, don't get too greedy looking for an ideal price point when CWBHF corrects. Cannabis Science (CBIS)On paper, Cannabis Science (OTCMKTS:CBIS) represents the next evolution among cannabis stocks: pharmaceutical firms that devote their time and research exclusively toward medical marijuana.Not only that, this is a much-needed development that could lift CBIS stock, as well as the entire botanical industry.For decades, people unquestionably trusted the mainstream healthcare and pharmaceutical network.However, the rapidly escalating opioid crisis has proven that well-intentioned medical professionals can lever a tragic impact. One of the underlying causes of this crisis is the addictiveness of prescribed medicines.Organizations like Cannabis Science can potentially mitigate this situation with naturally sourced therapies free of psychoactive side-effects. That's the allure for CBIS stock. However, shares trade for less than .03 cents a pop, so this is only for the risk-tolerant. GW Pharmaceuticals (GWPRF)On a surface level, GW Pharmaceuticals (OTCMKTS:GWPRF) brings a lot of positives to the table. As pioneers among medicinally-concentrated marijuana stocks, they lever substantial credibility.Source: Shutterstock Their Sativex drug for addressing symptoms associated with multiple sclerosis achieved better-than-expected results. This only encourages other companies to pursue cannabis-based therapies for many other diseases.That's the good news. The not-so-pleasant side of the coin, though, is market performance. While no one mistakes cannabis stocks as stable investment platforms, GWPRF stock is rough for even hardened botanical veterans.In December of last year, shares fell off a cliff before rebounding back toward low-earth orbit. Since then, it has added 69% so it's a really volatile stock. * 7 A-Rated Stocks Under $10 So is GWPRF stock worth a look now? Although I like how the company has stabilized, I don't care for its low volume. But GW Pharmaceuticals is a penny stock with underappreciated talents. If you have the nerve and the patience, it's worth your consideration.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Low-Priced Tech Stocks With Great Potential * 9 Stocks That Would Be Hurt By a Mexico/U.S. Border Closure * The Era of Car Ownership Is Over. And These 4 Charts Prove It The post 10 Medical Marijuana Stocks to Cure Your Portfolio appeared first on InvestorPlace.

  • 3M Stock Isn’t Crumbling, but It’s No Bargain Either

    3M Stock Isn’t Crumbling, but It’s No Bargain Either

    The decline in 3M (NYSE:MMM) continues. Despite an earnings beat, the quarterly report initiated another selloff in 3M stock.Source: Shutterstock Thankfully for longs, it did not happen in the dramatic fashion that affected the company in the first quarter.Nonetheless, it indicates MMM stock has not stopped falling. With stagnant growth forecasted and an ongoing trade war with no end in sight, I do not think investors should buy 3M at this time.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 8 Dividend Aristocrat Stocks to Buy Now No Matter What 3M Wins and Still DisappointsIn a previous article, I proposed that 3M stock would not recover until the trade war ended. Since Asia makes up more than 30% of company revenues, I still do not see how the company prospers with uncertainty clouding such a large percentage of its revenue.So far, this theory held up through second-quarter earnings. Even beating on both revenue and profits could not rescue the stock. Consequently, it has stagnated in the low-$160s per share level, near a point where it turned around in early June.I agree with my colleague James Brumley who stated that conglomerates in today's business world make much less sense. However, unlike Brumley, I do not think the time has come to start comparing 3M to General Electric (NYSE:GE). I need to see more bad news before I will start believing that it will fall that far.While I disagree with InvestorPlace contributor Josh Enomoto overall on 3M, I find myself almost as impressed with the packaging material called the "Flex and Seal Shipping Roll." It might even become their most popular creation in decades. MMM Isn't CheapUnfortunately for traders, cool products do not necessarily beget hot stocks. Even with the stock trading at bargain prices compared to this winter, I do not see the 2019 drop in MMM as enough.The forward price-to-earnings (PE) ratio of 17.2 stands well below S&P 500 averages. However, with profit growth expected to average 3.43% per year over the next five years, I would not call that multiple "cheap."Moreover, the current dividend yield of about 3.5% significantly exceeds the S&P 500 average yield of 1.91%. The six decades of annual payout hikes build further confidence in both the dividend and the company itself.Still, that payout now costs the company 67.55% of its net income, up from just 37% in 2011. While I do not think the company would end dividend hikes unless it was unavoidable, the payout has become a tremendous burden.However, as I implied earlier, any doomsday prediction is premature at this stage. Perhaps the company will spin off divisions to improve their focus. Maybe their packaging material or other product will bring investors back to 3M.Still, investors looking for a beleaguered stock in an established company with a decades-long history of dividend increases have more choices than 3M stock.Companies such as AT&T (NYSE:T) and AbbVie (NYSE:ABBV) offer forward multiples in the single digits and payouts which rise every year and offer a yield exceeding 5%. Moreover, the path to recovery for both equities appears more evident than that of MMM stock. The Bottom Line on 3M Stock3M faces too much uncertainty to buy at current levels. One might think an earnings beat would send MMM stock higher, particularly after the massive selloff that followed its first-quarter report.However, with its business in China facing uncertainty and its profit growth modest, investors have shown little inclination to pay 17.2 times forward earnings.Moreover, a dividend payout ratio approaching 70% should create concerns about its six-decade streak of payout hikes.3M is no GE. Company management still has time to turn this ship around. However, investors can find cheaper stocks which pay higher dividend yields and have a clearer path to recovery.As of this writing, Will Healy is long ABBV stock. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 8 Dividend Aristocrat Stocks to Buy Now No Matter What * 7 Stocks to Buy to Ride the Vegan Wave * 4 Safe Stocks to Buy Amid Trade War Turbulence The post 3M Stock Isna€™t Crumbling, but Ita€™s No Bargain Either appeared first on InvestorPlace.


    5 Big Pharma Showdowns to Watch

    The drug business can feel like a go-kart race, with big pharmaceutical giants and biotech startups knocking against each other as they scramble to be the first to market with the next big blockbuster.